TG Therapeutics announced that its CEO, Michael S. Weiss, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York City on June 3, 2026. The event will be webcast live on the company's website. TG Therapeutics is a biotechnology company focused on treatments for B-cell diseases and has FDA approval for BRIUMVI® to treat multiple sclerosis. This appearance highlights the company's ongoing engagement with investors and the healthcare community.
TG Therapeutics remains a "Strong Buy" as its drug BRIUMVI shows strong market momentum with 63% year-over-year sales growth in Q1. The company raised its 2026 BRIUMVI sales guidance to $885–$900 million, supported by successful Phase 3 trial results...
TG Therapeutics announced positive Phase 3 ENHANCE trial results demonstrating that a single 600 mg infusion of BRIUMVI for relapsing multiple sclerosis (RMS) provides bioequivalent drug exposure compared to the current two-dose initiation regimen. T...
TG Therapeutics announced presentations of new data on BRIUMVI (ublituximab-xiiy) for relapsing multiple sclerosis at the 2026 Consortium of Multiple Sclerosis Centers meeting. Data from the ongoing ENABLE Phase 4 study show significant patient-repor...
